Sol-gel and searchlight pharma announce licensing agreements to commercialize twyneo® and epsolay® in canada

Ness ziona, israel and montreal, june 06, 2023 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl) (“sol-gel”), an israel-based dermatology company and searchlight pharma inc. (“searchlight”), a private canadian specialty pharmaceutical company, today announced the signing of exclusive license agreements for twyneo and epsolay for the canadian market. twyneo and epsolay are two innovative, large-market, dermatology products that were developed by sol-gel. both products recently launched in the u.s., and searchlight is to commercialize them in canada over a fifteen-year term that is renewable for subsequent five-year periods.
SLGL Ratings Summary
SLGL Quant Ranking